高通量血液透析终末期肾病患者口服瑞舒伐他汀、辛伐他汀后血清炎症因子和血脂水平对比观察

Comparison of changes in serum inflammatory cytokines and lipid levels after oral administration of rosuvastatin and simvastatin in patients with end-stage renal disease receiving high-throughput maintenance hemodialysis

目的比较高通量血液透析终末期肾病患者口服瑞舒伐他汀、辛伐他汀后血清炎症因子和血脂水平变化。方法 78例终末期肾病患者随机分为瑞舒伐他汀组40例与辛伐他汀组38例,两组均接受高通量血液透析,瑞舒伐他汀组在此基础上口服瑞舒伐他汀,辛伐他汀组在此基础上口服辛伐他汀,比较两组血清炎症因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)]及血脂[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]。结果与辛伐他汀组比较,瑞舒伐他汀组治疗后血清hs-CRP、IL-6、TNF-α水平降低(P均<0.05);与同组治疗前比较,两组治疗后hs-CRP、IL-6、TNF-α水平降低(P均<0.05)。与辛伐他汀组比较,瑞舒伐他汀组治疗后LDL-C水平降低(P<0.05);与同组治疗前比较,两组治疗后TC、TG、LDL-C水平降低,HDL-C水平升高(P均<0.05)。结论瑞舒伐他汀、辛伐他汀均能降低血清hs-CRP、TNF-α、IL-6及TC、TG水平,升高LDL-C水平,但瑞舒伐他汀效果更佳。

Objective To compare the changes in serum inflammatory cytokines and lipid levels after oral administration of rosuvastatin and simvastatin in patients with end-stage renal disease receiving high-throughput maintenance hemodialysis.Methods Seventy-eight patients with end-stage renal disease were randomly divided into the rosuvastatin group and simvastatin group.Patients in the two groups received high-throughput maintenance hemodialysis,followed by oral administration of rosuvastatin in the rosuvastatin group and simvastatin in the simvastatin group.We compared the levels of serum inflammatory cytokines [high-sensitivity C-reactive protein（hs-CRP）,tumor necrosis factor-α（TNF-α）,and interleukin-6（IL-6）] and lipids [total cholesterol（TC）,triglyceride（TG）,low-density lipoprotein cholesterol（LDL-C）,high-density lipoprotein cholesterol（HDL-C） ].Results Compared with the simvastatin group,the levels of hs-CRP,IL-6,and TNF-α decreased after treatment in the rosuvastatin group（all P〈0.05）.The levels of hs-CRP,IL-6,and TNF-α significantly decreased after treatment in these two groups as compared with those before treatment（all P〈0.05）.Compared with the simvastatin group,LDL-C decreased after treatment in the rosuvastatin group（P〈0.05）.The levels of TC,TG,and LDL-C significantly decreased,while HDL-C increased after treatment in these two groups as compared with those before treatment（all P〈0.05）.Conclusion Both rosuvastatin and simvastatin can decrease the levels of hs-CRP,TNF-α,IL-6,TC,and TG,and increase the LDL-C level,but the efficacy of rosuvastatin is better than that of simvastatin.